Nektar Therapeutics <NKTR.O>: Wedbush cuts target price to $50 from $80
NKTR•Related News
Fidelity National Financial report finds borrowers ready to switch lenders for digital closings
FNF•
The Toro Company <TTC.N>: Oppenheimer initiates coverage with outperform rating; price target $120
TTC•
BIO-key Passkey:YOU wins FIDO Alliance full certification
BKYI•
Largo executes Banco do Brasil debt restructuring, covering 48% of US$82 million senior bank debt
LGO•
Amneal Pharma <AMRX.O>: Oppenheimer Initiates Coverage With Outperform Rating; Price Target $27
AMRX•